Resveratrol attenuates steatosis in obese Zucker rats by decreasing fatty acid availability and reducing oxidative stress

Gómez‐Zorita, Saioa; Fernández‐Quintela, Alfredo; Macarulla, M. T.; Aguirre, Leixuri; Hijona, Elizabeth; Bujanda, Luís; Milagro, Fermı́n I.; Martínéz, J. Alfredo; Portillo, Marı́a P.

doi:10.1017/s0007114511002753

Cited by 142 publications

(116 citation statements)

References 49 publications

Supporting

Mentioning

100

Contrasting

Order By: Relevance

“…Chang et al [26] found that BMI categories are positively correlated with an increased incidence of NAFLD, suggesting that obese patients might have an increased risk of developing NAFLD. Previous studies in rodent models have shown that resveratrol can inhibit NAFLD by decreasing body weight, as well as other obesity-related complications such as blood glucose and LDL-cholesterol [23,27]. According to the mentioned studies, anthropometric indexes have a crucial role in assessing resveratrol efficacy.…”

Section: Summary Of the Main Resultsmentioning

confidence: 99%

Resveratrol Supplementation in Patients with Non-Alcoholic Fatty Liver Disease: Systematic Review and Meta-analysis

Elgebaly¹,

Radwan²,

AboElnas³

et al. 2017

JGLD

View full text Add to dashboard Cite

Background: Resveratrol is a potential treatment option for management of non-alcoholic fatty liver disease (NAFLD) due to its anti-inflammatory, antioxidant properties, and calorie restriction-like effects. We aimed to synthesise evidence from published randomized clinical trials (RCTs) about the efficacy of resveratrol in the management of NAFLD.Methods: A computer literature search of PubMed, Scopus, Web of Science, and Cochrane Central was conducted using relevant keywords. Records were screened for eligible studies and data were extracted and synthesized using Review Manager Version 5.3 for windows. Subgroup analysis and sensitivity analysis were conducted.Results: Four RCTs (n=158 patients) were included in the final analysis. The overall effect estimates did not favor resveratrol group in terms of: serum ALT (MD -2.89, 95%CI [-15.66, 9.88], p=0.66), serum AST (MD -3.59, 95%CI [-13.82, 6.63], p=0.49), weight (MD -0.18, 95%CI [-0.92, 0.55], p=0.63), BMI (MD -0.10, 95 %CI [-0.43, 0.24], p=0.57), blood glucose level (MD -0.27, 95%CI [-0.55, 0.01], p=0.05), insulin level (MD -0.12, 95%CI [-0.69, 0.46], p=0.69), triglyceride level (MD 0.04, 95%CI [-0.45, 0.53], p=0.87), and LDL level (MD 0.21, 95%CI [-0.41, 0.83], p=0.51). Pooled studies were heterogeneous.Conclusion: Current evidence is insufficient to support the efficacy of resveratrol in the management of NAFLD. Resveratrol does not attenuate the degree of liver fibrosis or show a significant decrease in any of its parameters.Abbreviations: ALT: Alanine aminotransferase; AMPK: AMP-activated protein kinase; AST: Aspartate aminotransferase; BMI: Body mass index; CK-18: Cytokeratin-18; CRP: C-reactive protein; HC: Head circumference; HDL: High density lipoprotein; IL-6: Interleukin-6; LDL: Low density lipoprotein; MD: Mean difference; NAFLD: Non-alcoholic fatty liver disease; NASH: Non-alcoholic steatohepatitis; RCT: Randomized Controlled Trial; RR: Relative risk; SIRT1: Silent information regulation 2 homologue 1; TNF-α: Tumor necrosis factor α; WC: Waist circumference; WHR: Waist hip ratio.

show abstract

Section: Summary Of the Main Resultsmentioning

confidence: 99%

Resveratrol Supplementation in Patients with Non-Alcoholic Fatty Liver Disease: Systematic Review and Meta-analysis

Elgebaly¹,

Radwan²,

AboElnas³

et al. 2017

JGLD

View full text Add to dashboard Cite

show abstract

“…An intraperitoneal glucose tolerance test was performed in overnight (16 h)-fasted mice. Mice were injected with a bolus of 2 g of glucose/kg body weight, and blood glucose was measured in tail vein blood at 0, 15,30,45,60,90,120, and 180 min after injection using a handheld glucose meter (Accu-Chek, Roche Applied Science). To assess whole body metabolism through indirect calorimetry, mice were individually housed in metabolic chambers (CLAMS, Columbus Instruments) for 48 h after an initial acclimatization period.…”

Section: Methodsmentioning

confidence: 99%

Resveratrol and SRT1720 Elicit Differential Effects in Metabolic Organs and Modulate Systemic Parameters Independently of Skeletal Muscle Peroxisome Proliferator-activated Receptor γ Co-activator 1α (PGC-1α)

Svensson

Schnyder

Albert

et al. 2015

Journal of Biological Chemistry

View full text Add to dashboard Cite

Background: Resveratrol and SRT1720 elicit beneficial metabolic effects, supposedly through activation of PGC-1␣ in skeletal muscle. Results: Resveratrol/SRT1720 differentially affect transcriptional regulation in metabolic organs and modulates systemic parameters independently of muscle PGC-1␣. Conclusion: Skeletal muscle PGC-1␣ is largely dispensable for the systemic metabolic effects of resveratrol/SRT1720. Significance: Identifying molecular targets of resveratrol and SRT1720 is important to understand their therapeutic effect.

show abstract

“…Body weight and food intake were daily recorded. The doses of polyphenols were chosen based on previous studies [39][40][41]. …”

Section: Animals Diets and Serum Biochemical Parametersmentioning

confidence: 99%

Reshaping faecal gut microbiota composition by the intake of trans-resveratrol and quercetin in high-fat sucrose diet-fed rats

Etxeberría

Arias

Boqué

et al. 2015

The Journal of Nutritional Biochemistry

389

262

View full text Add to dashboard Cite

Diet-induced obesity is associated to an imbalance in the normal gut microbiota composition.Resveratrol and quercetin, widely known for their health beneficial properties, have low bioavailability and, when reach the colon, they are targets of the gut microbial ecosystem. Hence, the use of these molecules in obesity might be considered as a potential strategy to modulate intestinal bacterial composition. The purpose of this study was to determine whether trans-resveratrol and quercetin administration could counteract gut microbiota dysbiosis produced by high-fat sucrose diet (HFS) and in turn, improve gut health. Wistar rats were randomized into four groups fed a HFS diet supplemented or not with trans-resveratrol (15 mg/kg BW/day), quercetin (30 mg/kg BW/day) or a combination of both polyphenols at those doses. Administration of both polyphenols together prevented body-weight gain and reduced serum insulin levels. Moreover, individual supplementation of trans-resveratrol and quercetin effectively reduced serum insulin levels and insulin resistance.Quercetin supplementation generated a great impact on gut microbiota composition at different taxonomic levels, attenuating Firmicutes/Bacteroidetes ratio and inhibiting the growth of bacterial species previously associated to diet-induced obesity (Erysipelotrichaceae, Bacillus, Eubacterium 1 cylindroides). Overall, the administration of quercetin was found to be effective in lessening HFS dietinduced gut microbiota dysbiosis. In contrast, trans-resveratrol supplementation alone or in combination with quercetin, scarcely modified the profile of gut bacteria, but acted at intestinal level altering the mRNA expression of tight-junction proteins (TJPs) and inflammation associated genes.

show abstract

Resveratrol attenuates steatosis in obese Zucker rats by decreasing fatty acid availability and reducing oxidative stress

Cited by 142 publications

References 49 publications

Resveratrol Supplementation in Patients with Non-Alcoholic Fatty Liver Disease: Systematic Review and Meta-analysis

Resveratrol Supplementation in Patients with Non-Alcoholic Fatty Liver Disease: Systematic Review and Meta-analysis

Resveratrol and SRT1720 Elicit Differential Effects in Metabolic Organs and Modulate Systemic Parameters Independently of Skeletal Muscle Peroxisome Proliferator-activated Receptor γ Co-activator 1α (PGC-1α)

Reshaping faecal gut microbiota composition by the intake of trans-resveratrol and quercetin in high-fat sucrose diet-fed rats

Contact Info

Product

Resources

About